This inventor holds 6 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Anida Pharma, Inc., A.t. Resolve Sarl, Andida Pharma, Inc.. Active years: 2014-2020.
Company Filing History:
3 out of 3 
2 out of 2 
1 out of 1 Years Active: 2014-2020
Title: **Per Gjorstrup: Innovator in Ototoxicity Treatment**
Introduction
Per Gjorstrup is a notable inventor based in Cambridge, MA, specializing in innovative methods for treating ototoxicity. With six patents to his name, Gjorstrup has made significant contributions to the field of pharmaceutical compositions aimed at alleviating ear damage caused by various drugs and toxins.
Latest Patents
His latest patents focus on the use of DHA analogs and their pharmaceutical compositions to treat ototoxicity. Ototoxicity, which refers to damage to ear structures, particularly the cochlea and vestibular system, can lead to serious conditions such as irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo. Gjorstrup's work aims to provide effective solutions for individuals suffering from these debilitating effects.
Career Highlights
Throughout his career, Gjorstrup has worked with various companies, including Anida Pharma, Inc. and A.T. Resolve Sarl, where he has further developed his expertise in pharmaceutical innovations. His dedication to advancing medical treatments has established him as a respected figure in the field.
Collaborations
One of Gjorstrup's notable collaborators is C. Eric Schwartz, who has contributed to the development of his innovative projects. Their combined efforts have worked towards significant breakthroughs in the understanding and treatment of ototoxicity.
Conclusion
Per Gjorstrup's contributions to medical science through his patents and collaborations continue to pave the way for better therapeutic options for those affected by ear damage. His research exemplifies the importance of innovation in addressing complex health issues.